TRINITY MEDICAL GROUP INC
SB-2, EX-4.2, 2000-10-20
COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Previous: TRINITY MEDICAL GROUP INC, SB-2, EX-4.1, 2000-10-20
Next: TRINITY MEDICAL GROUP INC, SB-2, EX-4.3, 2000-10-20





FORM OF NOTE PAYABLE                                                 APPENDIX C

THIS NOTE HAS NOT BEEN REGISTERED  UNDER THE SECURITIES ACT OF 1933, AS AMENDED,
AND IS  TRANSFERABLE  ONLY UPON THE  CONDITIONS  SPECIFIED IN THE NOTE AGREEMENT
REFERRED TO HEREIN.

                                 PROMISSORY NOTE

$5,000                  San Rafael, California         Date:________ _____, 1999

         FOR VALUE RECEIVED,  the  undersigned,  Trinity Medical Group USA, Inc.
("Maker"),  hereby  promises  to pay to the  order  of  ________________________
("Payee"),  the principal sum of Five Thousand and no/100 Dollars  ($5,000),  in
lawful  money in United  States of  America,  which  shall be legal  tender,  in
payment  of all debts and dues,  public  and  private,  at the time of  payment,
bearing interest and payable as provided herein.

         Interest on the unpaid  balance of this Note shall  accrue at a rate of
10% per  annum;  provided,  however,  that such  interest  shall not  exceed the
Maximum Rate as hereinafter  defined.  All past-due principal and interest shall
bear interest at the maximum rate permitted by applicable law.  Interest will be
computed on the basis of a 360-day year of twelve 30-day months.

         All interest to be paid on this Note shall be payable, at the option of
the  Maker,  in either  cash or in shares of Maker  common  stock.  The value of
Maker's  common  stock shall be the Fair  Market  Value of the shares of Maker's
common stock, as defined in this Note.

         The "Fair  Market  Value" of a share of Maker  common stock on any date
shall be (i) the closing sales price on the immediately  preceding  business day
of a share of  Maker  common  stock  as  reported  on the  principal  securities
exchange on which  shares of Maker  common  stock are then listed or admitted to
trading or (ii) if not so  reported,  the  average of the  closing bid and asked
prices for a share of Maker common stock on the immediately  preceding  business
day as  quoted on the  National  Association  of  Securities  Dealers  Automated
Quotation System ("Nasdaq") or (iii) if not quoted on Nasdaq, the average of the
closing bid and asked  prices for a share of Maker common stock as quoted by the
National  Association of Securities  Dealers' OTC Bulletin Board System.  If the
price of a share of Maker common stock shall not be so reported, the Fair Market
Value of a share of Maker common stock shall be  determined by the Maker's Board
of Directors in its absolute discretion. In no event shall the Fair Market Value
of any share of Maker common stock be less than its par value.

         The principal amount and accrued interest of this Note shall be due and
payable on August, 30, 2001, provided however,  the principal amount and accrued
interest of this Note shall be due and payable  immediately  upon the occurrence
of either of the following  events:  (i) a Change in Control of Trinity  Medical
Group USA,  Inc., as defined in this Note,  or (ii) the  completion of an equity
financing  which raises in the aggregate at least  $250,000,  in the form of one
equity  transaction or in the form of a series of equity  transactions  within a
six month period.  The Note may be renewed for additional  thirty day periods at
the option of the holder.

         For the  purpose  of this  Note,  "Change  in  Control"  shall mean the
occurrence of any of the following events:

         (i)      any person  becomes,  after the issue  date of this Note,  the
                  "beneficial owner" (as defined in Rule 13d-3 promulgated under
                  the  Securities  Exchange Act of 1934,  as amended  ("Exchange
                  Act")),  directly or  indirectly,  of  securities of the Maker
                  representing  30% or more of the combined  voting power of the
                  Maker's  then  outstanding  securities,  unless  the  Board of
                  Directors of the Maker (as  constituted  immediately  prior to
                  such  Change  in  Control)  determines  in its  sole  absolute
                  discretion that no Change in Control has occurred;

         (ii)     Individuals who constitute the Board of Directors of the Maker
                  on the  issue  date of this Note  cease,  for any  reason,  to
                  constitute  at least a majority of the Board of  Directors  of
                  the  Maker;  provided,  however,  that any  person  becoming a
                  director  subsequent  to the  issue  date of this Note who was
                  nominated  for  election  by at  least  66%  of the  Board  of
                  Directors  of the Maker as

                                      C-1

<PAGE>

                  constituted  on the issue  date of this Note  (other  than the
                  nomination of an individual whose initial assumption of office
                  is in connection with an actual or threatened election contest
                  relating  to the  election  of the Board of  Directors  of the
                  Maker, as such terms are used in Rule 14a-11 of Regulation 14A
                  promulgated  under the Exchange Act) shall be, for purposes of
                  this Note,  considered  a member of the Board of  Directors of
                  the Maker as constituted on the issue date of this Note; or

         (iii)    the Board of Directors of the Maker determines in its sole and
                  absolute discretion that there has been a Change in Control of
                  the Maker.

         This Note may be prepaid in whole or in part, at any time and from time
to time, without premium or penalty.

         If any payment of  principal  or interest on this Note shall become due
on a Saturday,  Sunday or any other day on which national banks are not open for
business, such payment shall be made on the next succeeding business day.

         The  indebtedness  evidenced by this Note is unsecured and  subordinate
and  junior in right of  payment  to the  prior  payment  in full of all  senior
indebtedness (however defined in any debt instrument).

         Notwithstanding  anything  to the  contrary  in this  Note or any other
agreement entered into in connection herewith, whether now existing or hereafter
arising and whether  written or oral,  it is agreed  that the  aggregate  of all
interest  and  any  other  charges  constituting  interest,  or  adjudicated  as
constituting  interest,  and contracted for, chargeable or receivable under this
Note or  otherwise  in  connection  with this loan  transaction,  shall under no
circumstances exceed the Maximum Rate. In the event the maturity of this Note is
accelerated  by reason of an Event of Default under this Note,  other  agreement
entered into in  connection  herewith or therewith,  by voluntary  prepayment by
Maker or otherwise, then earned interest may never include more than the Maximum
Rate,  computed from the dates of each advance of the loan proceeds  outstanding
until  payment.  If from any  circumstance  any  holder of this Note  shall ever
receive interest or any other charges constituting  interest,  or adjudicated as
constituting  interest,  the amount, if any, which would exceed the Maximum Rate
shall be applied to the  reduction of the  principal  amount owing on this Note,
and not to the payment of interest;  or if such excessive  interest  exceeds the
unpaid balance of principal hereof,  the amount of such excessive  interest that
exceeds the unpaid  balance of principal  hereof shall be refunded to Maker.  In
determining  whether or not the  interest  paid or payable  exceeds  the Maximum
Rate, to the extent  permitted by applicable law (i) any  non-principal  payment
shall be  characterized  as an expense,  fee or premium rather than as interest;
and (ii) all interest at any time contracted for, charged, received or preserved
in connection  herewith  shall be amortized,  prorated,  allocated and spread in
equal parts  during the period of the full  stated  term of this Note.  The term
"Maximum  Rate" shall mean the maximum  rate of interest  allowed by  applicable
federal or state law.

         Except as  provided  herein,  Maker and any  sureties,  guarantors  and
endorsers of this Note jointly and severally waive demand,  presentment,  notice
of  nonpayment  or  dishonor,   notice  of  intent  to  accelerate,   notice  of
acceleration, diligence in collecting, grace, notice and protest, and consent to
all  extensions  without  notice for any  period or periods of time and  partial
payments, before or after maturity,  without prejudice to the holder. The holder
shall similarly have the right to deal in any way, at any time, with one or more
of the foregoing  parties  without  notice to any other party,  and to grant any
such party any extensions of time for payment of any of said indebtedness, or to
grant any other  indulgences  or forbearance  whatsoever,  without notice to any
other party and without in any way affecting the personal liability of any party
hereunder.  If any  efforts  are made to  collect  or  enforce  this Note or any
installment due hereunder,  the undersigned  agrees to pay all collection  costs
and fees, including reasonable attorney's fees.

         This Note shall be construed and enforced under and in accordance  with
the laws of the State of California.

         IN WITNESS WHEREOF, Maker has duly executed this Note as of the day and
year first above written.

                                                 TRINITY MEDICAL GROUP USA, INC.

                                                 By /s/ James S. Namnath
                                                   -----------------------------
                                                   James S. Namnath, Ph.D.

                                      C-2


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission